Details

Autor(en) / Beteiligte

• Horowitz, Mark A.
• Moncrieff, Joanna
• de Haan, Lieuwe
• Bogers, Jan P.A.M.
• Gangadin, Shiral S.
• Kikkert, Martijn
• Veling, Wim
• Sommer, Iris E. C.

Titel

Tapering antipsychotic medication: practical considerations

Ist Teil von

• Psychological medicine, 2022-01, Vol.52 (1), p.32-35

Ort / Verlag

Cambridge, UK: Cambridge University Press

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• In one qualitative survey conducted online, most respondents (70%) had tried to stop taking antipsychotics at least once, mainly due to unpleasant side effects (64%) and worries about long-term physical health (52%), while 35% reported that their quality of life was improved by antipsychotics and 56% thought that the drugs reduced the problems that they were prescribed for (Read & Williams, 2019). Many patients want to try to reduce or discontinue their antipsychotic medication. [...]75% of respondents in a UK-based survey among 172 clinicians working with first episode patients (Thompson, Singh, & Birchwood, 2016), thought that early discontinuation of antipsychotic medication after remission was beneficial for most patients. A recent systematic review has found that non-pharmacological interventions, like cognitive-behavioural therapy, Needs Adapted Treatment and Soteria have outcomes, including relapse, similar to usual care (Cooper, Laxhman, Crellin, Moncrieff, & Priebe, 2019), with encouraging but inconsistent findings for other non-pharmacological interventions. An individual approach Despite the overall patterns, there are large individual differences regarding dose occupancy, symptoms, self-management skills and people's social networks, which are reflected in variations in the tolerability of patients to different rates of tapering.